Drug Trial Radar · NCT02412787
Study of Long Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Participants Who Have Completed Study HGT-HIT-094
Last checked: Nov 20, 2026Latest source record: Jun 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
56
Actual
Start
Apr 14, 2015
Primary completion
Apr 18, 2024
Study completion Apr 18, 2024
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Apr 9, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This extension study will allow participants that completed Study HGT-HIT-094 to continue receiving Elaprase treatment in conjunction with idursulfase IT or to continue receiving Elaprase treatment and begin concurrent IT treatment for those that did not receive idursulfase IT treatment in Study HGT-HIT-094.
Conditions
- Hunter Syndrome
Interventions
Idursulfase-ITDrug
Participants received 10 mg of idursulfase-IT intrathecally via IDDD or LP once every 28 days. Participants who were younger than 3 years of age received an adjusted dose of 7.5 mg (\>8 months to 30 months of age) and 10 mg (\>30 months to 3 years of age).
ElapraseDrug
Participants received intravenous (IV) Elaprase infusions at a minimum of 48 hours after IT administration of idursulfase-IT.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs)Time frame: Up to 9 years
- Number of Participants With Clinically Significant Changes in Vital SignsTime frame: Up to 9 years
- Number of Participants With Clinically Significant Changes in Laboratory ParametersTime frame: Up to 9 years
- Number of Participants With Clinically Significant Changes in 12-lead Electrocardiogram (ECG) FindingsTime frame: Up to 9 years
- Maximum Observed Serum Concentration (Cmax) of IdursulfaseTime frame: Predose and at 30 min, 60 min, 120 min, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 30 hours and 36 hours post-dose at Week 100 in relation to HGT-HIT-094 (Week 48 of this study)
- Percent Change From Baseline in the Concentration of Glycosaminoglycan (GAG) in CSF at Month 67Time frame: For participants who began IT treatment in HGT-HIT-094: From Baseline of HGT-HIT-094 up to Month 67 in relation to HGT-HIT-094; For participants who began IT treatment in this study: From Baseline of this study up to Month 55 of this study.
- Percent Change From Baseline in the Concentration of GAG in Urine at Month 67Time frame: For participants who began IT treatment in HGT-HIT-094: From Baseline of HGT-HIT-094 up to Month 67 in relation to HGT-HIT-094; For participants who began IT treatment in this study: From Baseline of this study up to Month 55 of this study.
- Number of Participants Who Reported Positive for Anti-idursulfase Antibodies in CSFTime frame: Up to 9 years
- Number of Participants Who Reported Positive for Anti-idursulfase Antibodies in SerumTime frame: Up to 9 years
Locations
9 sites in 7 countries. Site status is shown where the registry gives one.
Children's Hospital and Research Center at Oakland
Oakland, California
Ann & Robert H Lurie Children's Hospital of Chicago
Chicago, Illinois
University of North Carolina
Chapel Hill, North Carolina
Women's and Children's Hospital
Adelaide, Australia
The Hospital for Sick Children
Toronto, Ontario, Canada
Hôpital Femme Mère Enfants
Bron, France
Instituto Nacional de Pediatría
Coyoacán, Mexico City, Mexico
Hospital Infantil Universitario Niño Jesus
Madrid, Spain
Royal Manchester Children's Hospital
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.